Actym Therapeutics, Inc. is a biotechnology company focused on developing novel immunotherapies for cancer treatment. They leverage their proprietary STACT (S. Typhimurium-Attenuated Cancer Therapy) platform to engineer bacteria that can selectively target and modulate the tumor microenvironment, enhancing the immune system's ability to combat cancer. Founded in 2017, Actym has made significant strides in preclinical development and is backed by leading venture capital firms. Their innovative approach aims to address unmet needs in oncology, positioning them as a promising player in the biotech industry.